HRP20170386T1 - Stabilizacija fsh - Google Patents

Stabilizacija fsh Download PDF

Info

Publication number
HRP20170386T1
HRP20170386T1 HRP20170386TT HRP20170386T HRP20170386T1 HR P20170386 T1 HRP20170386 T1 HR P20170386T1 HR P20170386T T HRP20170386T T HR P20170386TT HR P20170386 T HRP20170386 T HR P20170386T HR P20170386 T1 HRP20170386 T1 HR P20170386T1
Authority
HR
Croatia
Prior art keywords
formulation
fsh
use according
salt
amount
Prior art date
Application number
HRP20170386TT
Other languages
English (en)
Croatian (hr)
Inventor
Helen Ulrika Sjögren
Heidi Louise Bagger
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of HRP20170386T1 publication Critical patent/HRP20170386T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20170386TT 2010-07-30 2011-07-28 Stabilizacija fsh HRP20170386T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10171428A EP2417982A1 (en) 2010-07-30 2010-07-30 Stabilization of gonadotropins
PCT/EP2011/062986 WO2012013742A2 (en) 2010-07-30 2011-07-28 Stabilization of fsh
EP11736111.3A EP2598160B1 (en) 2010-07-30 2011-07-28 Stabilization of fsh

Publications (1)

Publication Number Publication Date
HRP20170386T1 true HRP20170386T1 (hr) 2017-05-05

Family

ID=43216624

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170386TT HRP20170386T1 (hr) 2010-07-30 2011-07-28 Stabilizacija fsh

Country Status (27)

Country Link
US (3) US8993732B2 (cg-RX-API-DMAC7.html)
EP (3) EP2417982A1 (cg-RX-API-DMAC7.html)
JP (3) JP5860047B2 (cg-RX-API-DMAC7.html)
KR (2) KR101991756B1 (cg-RX-API-DMAC7.html)
CN (2) CN103052398B (cg-RX-API-DMAC7.html)
AR (1) AR082776A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011284702C1 (cg-RX-API-DMAC7.html)
BR (1) BR112013002312B1 (cg-RX-API-DMAC7.html)
CA (1) CA2805864A1 (cg-RX-API-DMAC7.html)
DK (1) DK2598160T3 (cg-RX-API-DMAC7.html)
ES (1) ES2623634T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170386T1 (cg-RX-API-DMAC7.html)
HU (1) HUE033592T2 (cg-RX-API-DMAC7.html)
IL (2) IL223821A (cg-RX-API-DMAC7.html)
JO (1) JO3229B1 (cg-RX-API-DMAC7.html)
LT (1) LT2598160T (cg-RX-API-DMAC7.html)
MX (2) MX356951B (cg-RX-API-DMAC7.html)
NZ (2) NZ606366A (cg-RX-API-DMAC7.html)
PL (1) PL2598160T3 (cg-RX-API-DMAC7.html)
PT (1) PT2598160T (cg-RX-API-DMAC7.html)
RS (1) RS55772B1 (cg-RX-API-DMAC7.html)
RU (1) RU2574012C2 (cg-RX-API-DMAC7.html)
SA (1) SA114350786B1 (cg-RX-API-DMAC7.html)
SI (1) SI2598160T1 (cg-RX-API-DMAC7.html)
TW (1) TWI439283B (cg-RX-API-DMAC7.html)
WO (1) WO2012013742A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201209497B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
MX356383B (es) * 2013-11-12 2018-05-24 Cadila Healthcare Ltd Formulación líquida de gonadotropina estabilizada con polietilenglicol.
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种卵泡刺激素的长效制剂
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
FR3083089A1 (fr) * 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
CN111836616B (zh) 2017-12-07 2024-01-16 阿道恰公司 包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的ph 7为7的可注射溶液
BR112020011570A2 (pt) 2017-12-07 2020-12-08 Adocia Solução injetável a um ph 7 compreendendo pelo menos uma insulina basal apresentando um pi entre 5,8 e 8,5 e um co-poliaminoácido contendo cargas de carboxilato e radicais hidrofóbicos
FR3084584B1 (fr) * 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
FR3084586B1 (fr) * 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
JP7425459B2 (ja) * 2019-10-11 2024-01-31 株式会社シノテスト 安定化されたhmgb1含有溶液

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA61053C2 (en) 1995-03-21 2003-11-17 Applied Research Systems Stable liquid pharmaceutical compositions, method for its production and delivery form
AU738176B2 (en) * 1996-05-29 2001-09-13 Delsitech Oy Dissolvable oxides for biological applications
IL122732A0 (en) 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
KR20010083126A (ko) * 1998-07-23 2001-08-31 피터 지. 스트링거 여포자극 호르몬 및 여포자극 호르몬 변이체 제형, 제품및 방법
MXPA06011029A (es) * 2004-04-07 2007-01-25 Ares Trading Sa Formulacion liquida de hormona del crecimiento.
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
SI2249869T1 (sl) * 2008-02-08 2012-01-31 Biogenerix Ag Tekoäśa formulacija fsh
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
CN101614748A (zh) * 2008-06-25 2009-12-30 上海新波生物技术有限公司 促卵泡激素时间分辨免疫荧光分析法及试剂盒
MX2011013898A (es) * 2009-06-22 2012-05-22 Amgen Inc Proteínas replegadas que usan un estado de oxido-reduccion quimicamente controlado.
RU2553375C2 (ru) * 2010-02-12 2015-06-10 Интас Биофармасьютикалс Лимитед Жидкий состав фолликулостимулирующего гормона
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins

Also Published As

Publication number Publication date
AU2011284702B2 (en) 2015-05-14
US8993732B2 (en) 2015-03-31
MX2013000681A (es) 2013-02-27
CN103052398B (zh) 2015-09-16
US20150265681A1 (en) 2015-09-24
US20130210727A1 (en) 2013-08-15
AR082776A1 (es) 2013-01-09
SI2598160T1 (sl) 2017-07-31
MX356951B (es) 2018-06-21
AU2011284702A1 (en) 2013-02-07
ZA201209497B (en) 2013-08-28
US20170216405A1 (en) 2017-08-03
JP5860047B2 (ja) 2016-02-16
EP2417982A1 (en) 2012-02-15
JP6522711B2 (ja) 2019-05-29
RS55772B1 (sr) 2017-07-31
US9463221B2 (en) 2016-10-11
EP2598160A2 (en) 2013-06-05
SA114350786B1 (ar) 2015-07-09
CA2805864A1 (en) 2012-02-02
JO3229B1 (ar) 2018-03-08
BR112013002312B1 (pt) 2021-09-21
RU2574012C2 (ru) 2016-01-27
NZ606366A (en) 2014-08-29
JP2013532677A (ja) 2013-08-19
IL249920A0 (en) 2017-03-30
EP2598160B1 (en) 2017-02-22
KR101820115B1 (ko) 2018-01-18
MX341464B (es) 2016-08-22
KR101991756B1 (ko) 2019-06-21
EP3144010A1 (en) 2017-03-22
AU2011284702C1 (en) 2015-09-03
KR20180008916A (ko) 2018-01-24
CN103052398A (zh) 2013-04-17
JP2018048188A (ja) 2018-03-29
IL223821A (en) 2017-01-31
RU2012157154A (ru) 2014-09-10
LT2598160T (lt) 2017-04-10
JP2016102127A (ja) 2016-06-02
WO2012013742A3 (en) 2012-04-19
PL2598160T3 (pl) 2017-06-30
TWI439283B (zh) 2014-06-01
ES2623634T3 (es) 2017-07-11
TW201208694A (en) 2012-03-01
KR20130143692A (ko) 2013-12-31
HUE033592T2 (hu) 2017-12-28
WO2012013742A2 (en) 2012-02-02
DK2598160T3 (en) 2017-03-27
PT2598160T (pt) 2017-03-30
NZ628962A (en) 2016-01-29
BR112013002312A2 (pt) 2018-03-20
CN105106939A (zh) 2015-12-02

Similar Documents

Publication Publication Date Title
HRP20170386T1 (hr) Stabilizacija fsh
JP2013532677A5 (cg-RX-API-DMAC7.html)
MX2009013255A (es) Matriz de solidificacion que incluye una sal de un acido mono-, di- o tri-carboxilico saturado de cadena recta.
FI3810201T3 (fi) GIP/GLP1-agonistin koostumuksia
EP3437628A4 (en) COSMETIC COMPOSITION USING ALBUMINE, HYALURONIC ACID OR COLLAGEN AS AN ACTIVE IN CELL CULTURE MEDIUM
HRP20220793T1 (hr) Oftalmološki vodeni sastav
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
IT1383062B (it) Metodo per modulare la velocita' di rilascio di principi attivi microincapsulati
HRP20131173T4 (hr) Vodeni farmaceutski pripravci koji sadrže boratno-poliolne komplekse
RU2015122023A (ru) Стабилизированная композиция пеметрекседа
UY35859A (es) ?combinación farmacéutica que comprende amlodipina, losartán y rosuvastatina?.
MX340844B (es) Composición de limpieza.
PE20090951A1 (es) Suspension pediatrica estabilizada de carisbamato
RU2011108177A (ru) Ингибирующий буровой раствор
CL2014000035A1 (es) Composicion en forma de un gel para la preparacion de un producto alimenticio, que comprende agua en una cantidad de 30 a 70% en peso, saborizantes desde 1 a 40%, sal desde 10 a 25% y agentes gelificantes desde 0,15 a 12% que contienen al menos agar y xantano; y proceso para preparar dicha composicion.
AR105726A1 (es) Fluoro-inorgánicos para la acidificación o neutralización de sistemas de agua
MA32498B1 (fr) Compositions pharmaceutiques de rosuvastatine calcium
HRP20171592T1 (hr) Postupci i pripravci namijenjeni primjeni moksifloksacina u uho
HRP20191050T1 (hr) Pripravak protiv virusnog konjunktivitisa koji sadrži jota-karagenan
RU2013140665A (ru) Композиции для ухода за полостью рта
ES2487219T3 (es) Uso de un copolímero de N-vinillactama / vinilimidazol como agente de dispersión
FR2991178B1 (fr) Compositions topiques de type gel aqueux sous forme de suspension homogene d'un principe actif de la classe des retinoides contenant au moins une silice hydrophobe.
MX358604B (es) Composicion liquida acuosa que contiene acido 2-amino-3-(4-bromobenzoil) fenilacetico.
MX373026B (es) Composiciones antitranspirantes anhidras.
ES2528173A1 (es) Revestimiento proyectable aislante térmico y acústico